ArticleCancer science2018

Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.

Takashi Kojima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.